Sponsors
The bill improves consumer access to supplement information and strengthens regulatory traceability and oversight, at the cost of new compliance, legal risk, operational burdens for firms (especially small and foreign), potential confidentiality exposure, and additional federal spending.
Consumers (including people with allergies) will have a publicly searchable database showing supplement ingredients, directions, warnings, and allergen statements so they can verify safety and make more informed purchase choices.
Consumers and state/federal regulators will benefit from improved traceability and a funded FDA implementation, which can speed recalls, enforcement, and ongoing oversight of supplement products.
Supplement manufacturers, especially small firms, can reduce duplicative filings because a single electronic listing system and allowance to group identical formulations lowers paperwork and submission redundancy.
Small businesses and designated responsible persons must compile and submit detailed electronic product listings, creating new compliance costs and administrative burden.
Small businesses and responsible persons face increased legal and enforcement risk because failure to comply becomes a basis for misbranding and a prohibited act.
Foreign exporters and some small firms may struggle with mandatory electronic submissions and tight update windows (e.g., 30 days for label changes), creating operational challenges and potential market disruptions.
Based on analysis of 2 sections of legislative text.
Mandates electronic FDA listing of every dietary supplement with label and ingredient details, sets deadlines for listing/updates, and requires a public searchable database (with some confidential fields withheld).
Introduced January 15, 2026 by Richard Joseph Durbin · Last progress January 15, 2026
Requires manufacturers, packers, distributors (or their U.S. agents for foreign firms) to electronically submit detailed product-listing information for every dietary supplement marketed in the United States and gives the Secretary of Health authority to assign product-listing numbers and create a public, searchable database (with limited confidential fields redacted). The bill sets deadlines for existing and new products, requires timely updates and facility information on request, adds a new basis for misbranding for noncompliance, creates a new prohibited-act provision (text provided is truncated on that clause), protects specified confidential business information from disclosure, and authorizes roughly $7.9 million for FY2026 and $6.6 million annually for FY2027–2030 to carry out the law.